期刊文献+

ZKSCAN3在乳腺癌组织中的表达及其临床意义

Expression of ZKSCAN3 in breast cancer tissues and its significance
原文传递
导出
摘要 目的:探讨ZKSCAN3(zinc finger with KRAB and SCAN domains 3)在乳腺癌组织中的表达及其临床意义。方法 :应用免疫组织化学法检测120例乳腺癌组织及60例癌旁组织中ZKSCAN3蛋白的表达,并分析其与患者临床病理参数和总生存率之间的关系。进一步应用实时荧光定量PCR法和蛋白质印迹法检测乳腺癌组织及其相应癌旁组织中ZKSCAN3 m RNA和蛋白的表达水平。结果:乳腺癌组织中ZKSCAN3蛋白的阳性表达率[74%(89/120)]高于相应的癌旁组织[37%(22/60)](P<0.001)。ZKSCAN3蛋白的表达与乳腺癌患者肿块大小、淋巴结转移、分化程度和肿瘤分期相关(P值均<0.05),ZKSCAN3阳性表达患者的总生存率明显低于阴性患者(P=0.040)。乳腺癌组织中ZKSCAN3 m RNA和蛋白的表达水平均高于癌旁组织(P值均<0.01)。结论 :ZKSCAN3与乳腺癌的发生、进展及转移有关,可能是乳腺癌的促癌基因。 Objective: To investigate the expression of zinc finger with KRAB and SCAN domains 3(ZKSCAN3) in breast cancer tissues and its clinical significance.Methods: The expression of ZKSCAN3 in 120 specimens of human breast cancer tissues and 60 specimens of adjacent para-cancerous tissues was detected by immunohistochemistry, and its correlation with clinicopathological parameters and overall survival was analyzed. The real-time fluorescent quantitative PCR and Western blotting were used to further detect the expressions of ZKSCAN3 m RNA and proteinin breast cancer tissues and the adjacent para-cancerous tissues.Results: The positive expression rate of ZKSCAN3 protein in breast cancer tissues [74%(89/120)] was higher than that in the adjacent para-cancerous tissues [37%(22/60)](P 〈0.001). The expression of ZKSCAN3 protein was correlated with tumor size, lymph node metastasis, tumor differentiation and clinical stage of breast cancer(all P 〈0.05). The overall survival rate of patient with ZKSCAN3-positive breast cancer was significantly lower than that of patient with ZKSCAN3-negative breast cancer(P = 0.040). The expression levels of ZKSCAN3 m RNA and protein in breast cancer tissues were higher than those in the adjacent para-cancerous tissues(both P〈 0.01).Conclusion: ZKSCAN 3 is associated with the occurrence, progression and metastasis of breast cancer, so it may be an oncogene of breast cancer.
出处 《肿瘤》 CAS CSCD 北大核心 2017年第9期960-966,共7页 Tumor
关键词 乳腺肿瘤 基因表达 癌基因 ZKSCAN3基因 Breast neoplasms Gene expression Oncogenes ZKSCAN3 gene
  • 相关文献

参考文献1

二级参考文献39

  • 1HICKLIN D J,ELLIS L M.Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis[J].J Clin Oncol,2005,23(5):1011-1027.
  • 2NACHMAN R L,RAFII S.Platelets,petechiae,and preservation of the vascular waII[J].N Engl J Med,2008,359(12):1261-1270.
  • 3CHOWDURY M W,SCARAMUZZI R J,WHEELER-JONES C P,et al.The expression of angiogenic growth factors and their receptors in ovarian follicles throughout the estrous cycle in the ewe[J].Theriogeno/ogy,2010,73(7):856-872.
  • 4KERBEL R S.Tumor angiogenesis[J].N Engl J Med,2008,358(19):2039-2049.
  • 5VAZIRI S A,KIM J,GANAPATHI M K,et al,Vascular endothelial growth factor polymorphisms:role in response and toxicity of tyrosine kinase inhibitors[J].Curr Oncol Rep,2010,12(2):102-108.
  • 6JAIN R K.A new target for tumor therapy[J].N Engl J Med,2009,360(25):2669-2671.
  • 7HURWITZ H.Integrating the anti-VEGF-A humanized monoclonal antibody bevacizumab with chemotherapy in advanced colorectal cancer[J].Clin Co/orectal Cancer,2004,4(Suppl 2):562-S68.
  • 8HURWITZ H I,YI J,INCE W,et al.The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status:analysis of a phase Ⅲ study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer[J].Onco/ogist,2009,14(1):22-28.
  • 9KABBINAVAR F,IRL C,ZURLO A,et al,Bevacizumab improves the overall and progression-free survival of patients with metastatic colorectal cancer treated with 5-fluorouracil-based regimens irrespective of baseline risk[J] ,Oncology,2008,75(3-4):215-223.
  • 10KABBINAVAR F F,HURWITZ H I,YI J,et al.Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer:pooled analysis of cohorts of older patients from two randomized clinical trials[J].J Clin Oncol,2009,27(2):199-205.

共引文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部